Cytokinetics Incorporated (CYTK)
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
CYTK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $8.50B
- EPS (TTM)
- -$7.22
- Dividend yield
- None
- 52-week range
- 54.30 – 88.31
- Day range
- 60.15 – 62.05
- Volume / Avg
- 2.40M / 1.95M
- Beta
- —
- Shares outstanding
- 139.02M
- Next earnings
- Nov 4, 2026
52-week range
CYTK stock today
Cytokinetics (CYTK) closed at $61.12 on Oct 7, down 0.37% (-$0.23), versus the S&P 500's 0.22% decline. Shares are 30.8% below their 52-week high of $88.31, set on Jun 30, 2026 and 12.6% above the 52-week low of $54.30, in the middle of the past year's range. CYTK is down 3.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 1.6%.
Cytokinetics has posted a net loss over the last twelve months (EPS of -$7.22), so its P/E ratio is not meaningful. Cytokinetics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Cytokinetics
Company profileCytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert I. Blum
- Headquarters
- South San Francisco, CA
- Employees
- 673
- IPO year
- 2004
- Website
- cytokinetics.com
Financial highlights
Full financialsIn fiscal 2025, Cytokinetics generated $88.0 million in revenue, up 376.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Cytokinetics reported a net loss of $785.0 million, compared with a loss of $589.5 million a year earlier. Operating margin was -695.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $88.04M | $18.47M | $7.53M | $94.59M | $70.43M |
| Growth | +376.56% | +145.34% | -92.04% | +34.30% | +26.15% |
| Net income | $-784.96M | $-589.53M | $-526.24M | $-388.95M | $-215.31M |
| EPS (diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$109.90+79.81%
- Strong buy 7
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-1.52
- Last reported (Q2 2026)
- Aug 6, 2026
- EPS actual vs est.
- $-1.50 vs —
CYTK news
All CYTK newsCytokinetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs CYTK |
| TGTXTG Therapeutics Inc. | 52.95 | +1.46% | $8.11B | vs CYTK |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs CYTK |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs CYTK |
| PRAXPraxis Precision Medicines Inc. | 278.02 | -0.76% | $7.76B | vs CYTK |
| ABVXAbivax SA ADR | 87.01 | -1.37% | $7.59B | vs CYTK |
| IONSIonis Pharmaceuticals Inc. | 44.16 | +0.36% | $7.34B | vs CYTK |
| SYRESpyre Therapeutics Inc. | 80.85 | +0.92% | $7.13B | vs CYTK |
Indexes, lists and sector
Cytokinetics stock FAQ
What is Cytokinetics's stock price today?
CYTK last traded at $61.12 as of Oct 7, 4:00 PM EDT, down 0.37% on the day. Prices are delayed at least 15 minutes.
Does Cytokinetics pay a dividend?
No. Cytokinetics does not currently pay a regular cash dividend.
When is Cytokinetics's next earnings date?
Cytokinetics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-1.52.
Who is Cytokinetics's CEO?
Mr. Robert I. Blum is the chief executive officer of Cytokinetics Incorporated, which has about 673 employees.
Has CYTK ever split its stock?
Yes. The most recent CYTK stock split was a 1-for-6 split on Jun 25, 2013.
What is the CYTK 52-week high?
The 52-week high for CYTK is $88.31 and the 52-week low is $54.30. The stock is currently 30.8% below its high.